adminTraver Davis
Good morning. Traver Davis, health care sector specialist at Citi.
We’re going to kick off day 2 of our Global Healthcare Conference with Nuvation Bio. And with us from the company, we’re happy to have David Hung, who’s the Founder, President and CEO; as well as Philippe Sauvage, who is the CFO.
And I guess maybe the best way we could do this, I’ll give you the floor for a few minutes, if you want to sort of provide a bit of an overview of the company and the exciting things that you’re working on, and we’ll go into some Q&A.
David Hung
Founder, President, CEO & Chairman
Thanks so much, Traver. So I think we’re entering a very exciting phase for our company. We are now a commercial-stage company. We, as you know, acquired AnHeart Therapeutics a little over a year ago. And with that, we acquired 2 assets that we felt had great promise for us.
The first one was taletrectinib, which has now been approved, as of June 11 this year, under the brand name IBTROZI. And in our first full quarter of our launch, we had 204 new patient starts on this ROS1 drug for non-small cell lung cancer. And we’re excited about that because that’s about 6x the number of new patient starts for repotrectinib, which was the previous-generation ROS1 inhibitor. So we think that that molecule is really shaping up the way we had hoped for.
We had announced data recently showing now that, in addition to the nearly 90% response rate, our duration
Read the full article here
